Research
Hormonal
GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.
If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.
StrongSupportsHIGH confidence
These agents not only improve glycemic control and promote weight loss, but they also have favorable cardiovascular outcomes, renal protection, and overall mortality.
Why this rating
Cites multiple large-scale RCTs (SUSTAIN, STEP trials).
Source
Obesity as a Disease: A Primer on Clinical and Physiological Insights
Aayush Shah et al. · Methodist DeBakey Cardiovascular Journal · 2025
narrative_reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →